Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (51)	7/23/1998 9:19:00 AM
From: sam	Respond to of 1475

I've always wanted to own some Medimmune. ;)

To: scaram(o)uche who wrote (51)	7/24/1998 3:05:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

"In fact, on a recent trip to New York and Boston, I learned that hedge funds are now shorting biotech stocks selling as low as $4 a share,'' Fruedenthal said. ''These funds believe these stocks, even if they have good science, have no sponsorship and will end up drifting down to the $1 a share range. These companies will find it impossible to get financing. They're orphans." biz.yahoo.com One can't be more orphaned than BTRN is orphaned. :-) This, in my opinion, is a clear signal to find your favorite second- and third-tier companies and buy, buy, buy.